LeadStory

CNBC

'Billion dollar' weight-loss drug opportunity in India

CNBC · Just In
CNBC
CNBC
Just In

Ramesh Swaminathan, Executive Director and CFO of Lupin, says India’s weight-loss drug market could reach $1 billion, and expects Lupin to secure a strong share once semaglutide’s patent expires in March 2026. He also believes that the U.S. won't come out with tariffs on generic medicines and remains bullish on the company's prospects in the country.

Breakdown
  • Lupin plans to expand semaglutide, a weight-loss and diabetes drug, in India and South Africa, with Canada, Brazil, and China also targeted.
  • India is seen as a major market for semaglutide due to its high diabetes prevalence, with the opportunity estimated at nearly $1 billion. 19s
  • Lupin is optimistic about gaining a significant share of the Indian market, leveraging its strong position in diabetes and cardiovascular medicines. 39s
  • The company addresses potential U.S. regulatory and tariff challenges, noting that tariffs on generic medicines could raise public costs. 1m 10s
  • Lupin is investing in manufacturing and R&D in both India and the U.S., with facilities in Somerset and Florida, to support its global strategy. 2m 0s
HealthBusinessEconomy